HC Wainwright & Co. maintains Buy rating on Tyra Biosciences, $29 price target

HC Wainwright & Co. kept a Buy rating on Tyra Biosciences (TYRA) with a $29 price target, suggesting a 13.1% upside from the Sep 21 close. The firm highlights Tyra's pipeline and SNAP platform as strengths.

Original reporting
Published Sep 22, 2026, 10:19 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 11:27 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
HC Wainwright & Co. maintains Buy rating on Tyra Biosciences, $29 price target — source image
Decision brief

The 30-second read

$TYRABullishMed
01

Why it matters

Potential price lift toward $29 target; investors may adjust positions.

02

Market read

Analyst upgrade provides a fresh catalyst for a micro‑cap biotech stock.

03

What to watch

Upcoming trial results could override analyst optimism.

Relevance 6/10Novelty 5/10Timing: today

Background

Analyst note from HC Wainwright updating coverage on Tyra Biosciences.

Company-level read

Ticker impact

$TYRABullishMedium confidence
Context

HC Wainwright maintained a Buy rating on Tyra Biosciences and set a new $29 price target.

Expected impact

Potential modest upside of ~10% if market follows the rating.

Evidence & confidence

Buy rating and higher target provide a fresh catalyst for price appreciation.

Market effects

May boost sentiment toward small‑cap biotech peers.

Limited to US biotech market.

Minimal global impact.

Counterpoint

Rating could be premature without clinical data.

Key entities

  • Tyra Biosciences

    Biotech firm developing FGFR inhibitors.

  • HC Wainwright & Co.

    Equity research house issuing the rating.

Related articles

$TYRAMed

Tyra Biosciences 3Q 2026: EPS ($0.74) — 10-Q Summary

Tyra Biosciences reported a wider net loss in 3Q 2026, with R&D costs rising due to dabogratinib trials and headcount growth. Net loss was $51.12M, and diluted EPS was ($0.74). The company has $700.5M in cash, expected to last through 2030. Dabogratinib trials showed initial positive results.

$TYRAHighAI 8/10

Raymond James reiterates Strong Buy on Tyra Biosciences stock

Raymond James reiterated a Strong Buy rating and $50 price target for Tyra Biosciences (NASDAQ:TYRA) after a discussion with its CEO. The stock trades at $20.93, with analyst targets ranging from $29 to $59. Tyra's lead asset, dabogratinib, showed promising Phase 2 data for non-muscle invasive bladder cancer, with a 100% overall response rate at a 60 mg dose. Raymond James projects $2 billion in combined revenue by 2035 from Tyra's three opportunities.

$TYRAMedAI 8/10

Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported?

Tyra Biosciences (TYRA) reported Phase 2 trial results for dabogratinib, showing a 57% complete response rate in patients with FGFR3-altered bladder cancer. The study met its primary endpoint, with 79% objective response rate. The company plans further enrollment and regulatory discussions for Phase 3 design. Safety data showed no severe adverse events at the 60 mg dose.